NL2035805A - Method for preparing enzyme distillate and application thereof as eye care solution - Google Patents
Method for preparing enzyme distillate and application thereof as eye care solution Download PDFInfo
- Publication number
- NL2035805A NL2035805A NL2035805A NL2035805A NL2035805A NL 2035805 A NL2035805 A NL 2035805A NL 2035805 A NL2035805 A NL 2035805A NL 2035805 A NL2035805 A NL 2035805A NL 2035805 A NL2035805 A NL 2035805A
- Authority
- NL
- Netherlands
- Prior art keywords
- fermentation
- distillate
- eye care
- enzyme
- care solution
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 30
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000000855 fermentation Methods 0.000 claims abstract description 21
- 230000004151 fermentation Effects 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 7
- 239000011707 mineral Substances 0.000 claims abstract description 7
- 238000010565 inoculated fermentation Methods 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 4
- 230000032683 aging Effects 0.000 claims abstract description 4
- 238000004821 distillation Methods 0.000 claims abstract description 4
- 241000589212 Acetobacter pasteurianus Species 0.000 claims description 9
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 9
- 244000286779 Hansenula anomala Species 0.000 claims description 9
- 235000014683 Hansenula anomala Nutrition 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 8
- 229920001817 Agar Polymers 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 239000008121 dextrose Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 244000201986 Cassia tora Species 0.000 claims description 5
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 5
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 5
- 244000000626 Daucus carota Species 0.000 claims description 5
- 235000002767 Daucus carota Nutrition 0.000 claims description 5
- 244000119298 Emblica officinalis Species 0.000 claims description 5
- 235000015489 Emblica officinalis Nutrition 0.000 claims description 5
- 244000167230 Lonicera japonica Species 0.000 claims description 5
- 235000017617 Lonicera japonica Nutrition 0.000 claims description 5
- 241000037831 Polygonatum sibiricum Species 0.000 claims description 5
- 244000251905 Pseudocydonia sinensis Species 0.000 claims description 5
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 claims description 5
- 235000011449 Rosa Nutrition 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 244000077233 Vaccinium uliginosum Species 0.000 claims description 5
- 235000011720 Vaccinium uliginosum Nutrition 0.000 claims description 5
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 229910001414 potassium ion Inorganic materials 0.000 claims description 3
- 229910001415 sodium ion Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims 6
- 238000010564 aerobic fermentation Methods 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 2
- 238000009630 liquid culture Methods 0.000 claims 2
- 239000012869 germination medium Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 10
- 208000003464 asthenopia Diseases 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 4
- 210000001525 retina Anatomy 0.000 abstract description 4
- 238000012258 culturing Methods 0.000 abstract description 3
- 230000004377 improving vision Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 16
- 230000003385 bacteriostatic effect Effects 0.000 description 14
- 241000222122 Candida albicans Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000486634 Bena Species 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/02—Acetobacter
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
The present invention discloses a method for preparing enzyme distillate and the application thereof as an eye care solution. A method for preparing enzyme distillate 5 includes the following steps: strain culturing; inoculated fermentation; and aging: transferring, after fermentation, to a storage tank for anaerobic fermentation at a normal temperature for 180 days, and distilling with a distillation equipment to prepare the enzyme distillate. The liquid obtained by distilling the enzyme of the present invention has functions of maintaining retina and improving vision. Components of an eye care lO solution and mass percentages thereof include: enzyme distillate 80%, normal saline 15%, and mineral energy water 5%. The eye care solution of the present invention has no irritation, is not a drug, and has functions of relieving visual fatigue and inhibiting bacteria in the eyes.
Description
METHOD FOR PREPARING ENZYME DISTILLATE AND APPLICATION
THEREOF AS EYE CARE SOLUTION
[01] The present invention relates to the technical field of eye care solutions, and in particular to a method for preparing enzyme distillate and the application thereof as an eye care solution.
[02] As people's lifestyles and working conditions change, more and more time is spent with the eyes, such as watching computers, watching TV, and playing video games for long periods; it is easy to suffer from visual fatigue and dry eye, especially those who often wear framed eyeglass cases and contact lenses need to pay more attention to the care of the eyes. Eye care solution has become a popular eye care and health product in recent years, with the functions of rinsing, moistening, and cleaning the eyes. It can relieve eye fatigue to a certain extent, especially for people who watch computers or have contact lenses for a long time.
[03] The existing eye care solution can only temporarily relieve eye dryness, unable to maintain retina and improve vision, and contains irritation, which is prone to discomfort symptoms in the process of use. Moreover, it is a drug, which cannot relieve eye fatigue and inhibit bacteria in the eyes, does not have the function of improving eyesight, has low practicality, and is not convenient for people to use.
[04] In view of the problems in the related art, the present invention proposes a method for preparing enzyme distillate and the application thereof as an eye care solution, to overcome the above technical problems existing in the related art. The eye care solution in the present invention has no irritation, is not a drug, and has functions of relieving visual fatigue and inhibiting bacteria in the eyes; the liquid obtained by distilling the enzyme has functions of maintaining retina and improving vision.
[05] In order to achieve the above objects, the present invention provides the following technical solutions:
[06] The present invention provides a method for preparing enzyme distillate, including the following steps:
[07] (1) strain culturing
[08] L strains: wickerhamomyces anomalus CICC 1312, acetobacter pasteurianus
CICC 20002, lactobacillus acidophilus CICC6096, and bifidobacterium adolescentis
CICC6180; and
[09] II, seed medium: malt extract medium, dextrose agar medium, MRS broth medium;
[10] aerobically fermenting wickerhamomyces anomalus CICC 1312 with the malt extract medium at 28°C for 36 hours, aerobically fermenting acetobacter pasteurianus CICC 20002 with the dextrose agar medium at 30°C for 24 hours, and anaerobically fermenting lactobacillus acidophilus and bifidobacterium adolescentis with the MRS broth medium at 37°C for 24 hours;
[11] (2) inoculated fermentation
[12] inoculating the cultured strains into a fermentation medium according to a proportion (0.5% wickerhamomyces anomalus, 1% acetobacter pasteurianus, 1.5% lactobacillus acidophilus and bifidobacterium adolescentis), with fermentation conditions being aerobically fermented at 35°C for 3 days, followed by anaerobically fermented at 30°C for 3 days; and
[13] (3) aging
[14] transferring, after fermentation, to a storage tank for anaerobic fermentation at a normal temperature for 180 days, and distilling with a distillation equipment to prepare the enzyme distillate.
[15] Preferably, each component of the fermentation medium in step (2) is a medicinal and edible homologous raw material, and each component and the content thereof include: lonicera japonica 1 to 3.5 g/L, dendranthema morifolium 1 to 3 g/L, polygonatum sibiricum 0.5 to 2.5 g/L, rosa roxbunghii 3 to 5 g/L, daucus carota 1 to 4 g/L, phyllanthus emblica 1 to 4 g/L, chaenomeles sinensis 2 to 4 g/L, vaccinium uliginosum L. 2 to 5 g/L, catsia tora linn 0.5 to 2 g/L, and sucrose 15 to 25 g/L.
[16] The present invention provides an eye care solution, and components of the eye care solution and mass percentages thereof include: enzyme distillate 80%, normal saline 15%, and mineral energy water 5%.
[17] Preferably, the mineral energy water includes potassium ions, magnesium ions, calcium ions, sodium ions, and metasilicic acid.
[18] The present invention provides a method for preparing the eye care solution, including the following steps:
[19] a. dosing;
[20] b. stirring;
[21] c. ultrasonic disruption;
[22] d. microporous membrane filtration; and
[23] e. sterilization.
[24] Preferably, in step d, the membrane has a specification of 0.22 um.
[25] Preferably, in step e, the sterilization has a temperature of 105°C, and the sterilization has a duration of 15 minutes.
[26] Preferably, in step c, the ultrasonic disruption has a frequency of 15 to 20
KhZ, and the ultrasonic disruption has a duration of 3 to 6 minutes.
[27] Compared to the prior art, the advantageous effects of the present invention are:
[28] (1) The present invention is a method for preparing enzyme distillate and the application thereof as an eye care solution. By setting each component of a fermentation medium to be a medicinal and edible homologous raw material and the enzyme obtained by inoculated fermentation, the efficacy of the medicinal and edible homologous raw material is retained, and a large molecule is changed to a small molecule, which is not a drug and has no irritation, with strong practicability.
[29] (2) The present invention is a method for preparing enzyme distillate and the application thereof as an eye care solution; the components of the enzyme distillate, detected by GC-MS, contain unsaturated fatty acids with the effects of maintaining the retina and improving vision.
[30] (3) The present invention is a method for preparing enzyme distillate and the application thereof as an eye care solution; the eye care solution prepared, through antibacterial experiment testing, has an effect of inhibiting bacteria in the eyes, relieving visual fatigue, and having an auxiliary effect on related eye diseases.
[31] The technical solutions in the embodiments of the present invention will be described clearly and completely below in combination with the embodiments of the present invention. Clearly, the described embodiments are not all but only part of the embodiments of the present invention. All other embodiments, obtained by those ordinarily skilled in the art based on the embodiments in the present invention without creative work, shall fall within the scope of protection of the present invention.
[32] Embodiment
[33] A method for preparing enzyme distillate includes the following steps:
[34] (1) strain culturing
[35] L strains: wickerhamomyces anomalus CICC 1312, acetobacter pasteurianus
CICC 20002, lactobacillus acidophilus CICC6096, and bifidobacterium adolescentis
CICC6180; and
[36] II, seed medium: malt extract medium, dextrose agar medium, MRS broth medium;
[37] aerobically fermenting wickerhamomyces anomalus CICC 1312 with the malt extract medium at 28°C for 36 hours, aerobically fermenting acetobacter pasteurianus CICC 20002 with the dextrose agar medium at 30°C for 24 hours, and anaerobically fermenting lactobacillus acidophilus and bifidobacterium adolescentis with the MRS broth medium at 37°C for 24 hours;
[38] (2) inoculated fermentation
[39] inoculating the cultured strains into a fermentation medium according to a proportion (0.5% wickerhamomyces anomalus, 1% acetobacter pasteurianus, 1.5% lactobacillus acidophilus and bifidobacterium adolescentis), with fermentation conditions being aerobically fermented at 35°C for 3 days, followed by anaerobically fermented at 30°C for 3 days; and
[40] (3) aging
[41] transferring, after fermentation, to a storage tank for anaerobic fermentation at a normal temperature for 180 days, and distilling with a distillation equipment to prepare the enzyme distillate.
[42] In the embodiment, compounds with a matching degree greater than 80 degrees are selected by GC-MS data analysis using the peak area relative normalization method; there are 67 kinds of volatile components in enzyme distillate,
including 10 kinds of alcohols, 15 kinds of esters, 9 kinds of acids, 5 kinds of others, 8 kinds of alkanes, 7 kinds of alkenes, 7 kinds of aldehydes, and 9 kinds of aromatics.
[43] Preferably, Preferably, each component of the fermentation medium in step (2) is a medicinal and edible homologous raw material, and each component and the content thereof include: lonicera japonica 1 to 3.5 g/L, dendranthema morifolium 1 to 3 g/L, polygonatum sibiricum 0.5 to 2.5 g/L, rosa roxbunghii 3 to 5 g/L, daucus carota 1 to 4 g/L, phyllanthus emblica 1 to 4 g/L, chaenomeles sinensis 2 to 4 g/L, vaccinium uliginosum L. 2 to 5 g/L, catsia tora linn 0.5 to 2 g/L, and sucrose 15 to 25 g/L; more preferably, lonicera japonica 2 g/L, dendranthema morifolium 2 g/L, polygonatum sibiricum 1 g/L, rosa roxbunghii 4.5 g/L, daucus carota 2.5 g/L, phyllanthus emblica 2 g/L, chaenomeles sinensis 2.5 g/L g/L, vaccinium uliginosum L. 3g/L, catsia tora linn 1g/L, and sucrose 20g/L.
[44] In the embodiment, each component of the fermentation medium in step (2) is a medicinal and edible homologous raw material, and each component and the content thereof include: lonicera japonica 2 g/L, dendranthema morifolium 2 g/L, polygonatum sibiricum 1 g/L, rosa roxbunghii 4.5 g/L, daucus carota 2.5 g/L, phyllanthus emblica 2 g/L, chaenomeles sinensis 2.5 g/L, vaccinium uliginosum L. 3 g/L, catsia tora linn 1 g/L, and sucrose 20 g/L.
[45] The present invention provides an eye care solution, and components of the eye care solution and mass percentages thereof include: enzyme distillate 80%, normal saline 15%, and mineral energy water 5%.
[46] In the embodiment, the enzyme distillate is prepared by the method for preparing enzyme distillate.
[47] Preferably, the mineral energy water includes potassium ions, magnesium ions, calcium ions, sodium ions, and metasilicic acid.
[48] The present invention provides a method for preparing the eye care solution, including the following steps:
[49] a. dosing;
[50] b. stirring;
[51] c. ultrasonic disruption;
[52] d. microporous membrane filtration; and
[53] e. sterilization.
[54] Preferably, in step d, the membrane has a specification of 0.22 um.
[55] Preferably, in step e, the sterilization has a temperature of 105°C, and the sterilization has a duration of 15 minutes.
[56] Preferably, in step c, the ultrasonic disruption has a frequency of 15 to 20
KhZ, and the ultrasonic disruption has a duration of 3 to 6 minutes.
[57] Suspension quantitative bacteriostatic test of enzyme distillate on escherichia coli, staphylococcus aureus, and candida albicans
[58] I. Equipment
[59] 1. Sample information: enzyme distillate stoste was used as test substance
[60] 2. Test strains:
[61] escherichia coli (8099) was provided by Guangdong Food Microbiological
Safety Engineering Technology Research and Development Center and cultured for the third generation.
[62] Staphylococcus aureus (ATCC6538) was provided by BeNa Culture
Collection (BNCC) and cultured for the third generation.
[63] Candida albicans (ATCC10231) was provided by BNCC and cultured for the third generation.
[64] 3. Media: NA/20220815, SDA/20220812
[65] 4. Instruments and equipment: biological safety cabinet BSC-1604B2 (WPE-
RHO311), electro-heating standing-temperature cultivator DHP-9272 (WPE-RH0501), and water bath DC0510 (WPE-RHO327)
[66] II. Methods
[67] 1. Test basis: WS/T 650-2019 Antimicrobial and Bacteriostatic Effect
Evaluation Method 5.1.1 Suspension quantitative bacteriostatic test
[68] 2. Detection environment: temperature: 25.0 °C, humidity: 48% RH (escherichia coli, staphylococcus aureus), temperature: 24.7°C, humidity: 49% RH (candida albicans)
[69] 3. Bacteriostatic effect: the test substance acted for 20 minutes, and the test was repeated for 3 times
[70] III. Results
[71] Suspension quantitative bacteriostatic test detection results of escherichia coli, staphylococcus aureus, and candida albicans were shown in Table 1, Table 2, and
Table 3 below:
[72] Table 1 Suspension quantitative bacteriostatic test results of escherichia coli
Test number Number of | Number of viable bacteria in the viable bacteria sample at different time of in positive action (CFU/mL )/bacteriostatic control group rate (%) (CFU/mL)
[73]
[74]
[75] Note: negative control group: PBS, no bacterial growth on media
[76] Table 2 Suspension quantitative bacteriostatic test results of staphylococcus aureu
Test number Number of | Number of viable bacteria in the viable bacteria sample at different time of in positive action (CFU/mL)/bacteriostatic control group rate (%) (CFU/mL)
[77]
[78] Note: negative control group: PBS, no bacterial growth on media
[79] Table 3 Suspension quantitative bacteriostatic test results of candida albicans
Test number Number of | Number of viable bacteria in the viable bacteria sample at different time of in positive action (CFU/mL)/bacteriostatic or
[80] [ew [ew [er
[81] Note: negative control group: PBS, no bacterial growth on media TV.
Conclusion
[82] After three repeated tests, the bacteriostatic rate of the sample against escherichia coli, staphylococcus aureus, and candida albicans was equal to or greater than 50% to 90% after 20 minutes of action; the product had bacteriostatic effect, which complied with the requirements of 5.1.1.5 in WS/T 650-2019 Antimicrobial and
Bacteriostatic Effect Evaluation Method.
[83] In the present invention, unless expressly specified and limited otherwise, the terms "mounted", "disposed", "connected", "fixed", "screwed", and the like are to be construed broadly, for example, may be a fixed connection, a detachable connection, or an integral connection, may be a mechanical connection or an electrical connection, may be directly connected or indirectly connected through an intermediate medium, may be connected within two elements or may be in an interactive relationship between two elements. Unless otherwise specifically defined, the meaning of the above terms in the present invention will be understood by the ordinarily skilled in the art as the case may be.
[84] While embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions, and alterations may be made to these embodiments without departing from the principles and spirit of the present invention, the scope of which is defined by the appended claims and their equivalents.
Claims (8)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211143205.6A CN115475116A (en) | 2022-09-20 | 2022-09-20 | Preparation method of ferment distillate and application of ferment distillate as eye care solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2035805A true NL2035805A (en) | 2024-03-26 |
Family
ID=84424142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2035805A NL2035805A (en) | 2022-09-20 | 2023-09-15 | Method for preparing enzyme distillate and application thereof as eye care solution |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115475116A (en) |
| NL (1) | NL2035805A (en) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600061A (en) * | 2012-03-06 | 2012-07-25 | 吉林敖东大高酵素有限公司 | Preparation method for plant enzyme skin care liquid |
| CN106173613B (en) * | 2014-10-08 | 2019-10-25 | 中国科学院上海生命科学研究院 | A method of fruits and vegetables or cereal or integration of drinking and medicinal herbs ferment health food are prepared using probiotics fermention |
| CN104543844A (en) * | 2015-01-26 | 2015-04-29 | 杨志刚 | Blueberry enzyme |
| CN105124577B (en) * | 2015-09-01 | 2018-01-02 | 福建天斯顿生物科技有限公司 | A kind of preparation method of pectase |
| CN105105134A (en) * | 2015-09-24 | 2015-12-02 | 上海韬鸿化工科技有限公司 | Blueberry enzyme and preparation method thereof |
| CN109875039A (en) * | 2019-03-20 | 2019-06-14 | 广东利泰大健康产业股份有限公司 | A kind of preparation process of mixed bacterium stepwise fermentation emblic ferment product and the ferment product of preparation |
| CN110237160A (en) * | 2019-07-17 | 2019-09-17 | 广西天缘绿生物科技有限公司 | Eye cold compress condensation |
| CN113197987A (en) * | 2021-05-07 | 2021-08-03 | 山东凯漫生物科技有限公司 | Preparation method and application of eye care solution |
| CN114246814A (en) * | 2022-01-25 | 2022-03-29 | 湖北恩景生物科技有限公司 | Enzyme eye care solution |
-
2022
- 2022-09-20 CN CN202211143205.6A patent/CN115475116A/en active Pending
-
2023
- 2023-09-15 NL NL2035805A patent/NL2035805A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115475116A (en) | 2022-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abbas et al. | Antimicrobial activity of coconut oil and its derivative (lauric acid) on some selected clinical isolates | |
| CN102031229B (en) | Lactobacillus plantarum with gastrointestinal adsorption capacity and cholesterol removing capacity | |
| CN101328469B (en) | Streptococcus thermophilus grx02 having alcoholic liver damage protection function and use thereof | |
| CN113413351B (en) | Fermented liquid and fermented polypeptide with whitening and anti-aging effects, and preparation methods and applications thereof | |
| CN113143812B (en) | Preparation method of kava pepper fermentation product, kava pepper fermentation product and application of kava pepper fermentation product in cosmetics | |
| CN110964673B (en) | Pediococcus pentosaceus with high oxidation resistance and whitening effect and application thereof | |
| CN114634899B (en) | Lactobacillus fermentum and application thereof | |
| Jin et al. | Oplopanax elatus adventitious root production through fed-batch culture and their anti-bacterial effects | |
| CN115927096A (en) | Medicine and food homologous enzyme with uric acid reducing effect and preparation method thereof | |
| CN114645001A (en) | Lactobacillus paracasei and application thereof in preparation of product for regulating skin microecological system | |
| CN111904909B (en) | Dandruff removing scalp essence containing rose fermentation liquor and preparation method thereof | |
| CN116376731B (en) | Application of Wilkham yeast in preparing Prinsepia utilis extract | |
| CN115786182B (en) | Bifidobacterium animalis and application thereof | |
| NL2035805A (en) | Method for preparing enzyme distillate and application thereof as eye care solution | |
| CN105543141B (en) | A kind of norcholesterol bacteria preparation and its preparation method and application | |
| CN115927128B (en) | Transparent tremella fermentation product and preparation method and application thereof | |
| Rizal et al. | The effects of low-temperature storage on the viability of Lactobacillus casei and the stability of antibacterial activity in green grass jelly synbiotic drinks | |
| CN110721136A (en) | Preparation method and application of cosmetic raw material containing Kangpu tea | |
| KR101697535B1 (en) | Lactobacillus plantarum strain isolated by Rubus occidentalis and food composition comprising the same | |
| CN107410479B (en) | Fermented milk and preparation method thereof | |
| CN105263471A (en) | Moisturizing agent | |
| CN112741113B (en) | Microbial preparation for preventing and treating potato early blight and application thereof | |
| CN115645330B (en) | Pelargonium extract and preparation method and application thereof | |
| Utama et al. | Antibacterial Activity Test of Indigenous Yeast from Sapodilla Fruit against Staphylococcus aureus and Escherichia coli | |
| Prasad et al. | Fate of acidity and alcohol during fermentation of Salalah and Sri Lanka coconut water |